Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Oncogenic MYC Induces the Impaired Ribosome Biogenesis Checkpoint and Stabilizes p53, Independent of Increased Ribosome Content.

Morcelle C, Menoyo S, Morón-Duran FD, Tauler A, Kozma SC, Thomas G, Gentilella A.

Cancer Res. 2019 Jul 10. pii: canres.2718.2018. doi: 10.1158/0008-5472.CAN-18-2718. [Epub ahead of print]

PMID:
31292158
2.

Mitochondrial Complex I Activity Is Required for Maximal Autophagy.

Thomas HE, Zhang Y, Stefely JA, Veiga SR, Thomas G, Kozma SC, Mercer CA.

Cell Rep. 2018 Aug 28;24(9):2404-2417.e8. doi: 10.1016/j.celrep.2018.07.101.

3.

Phenformin-Induced Mitochondrial Dysfunction Sensitizes Hepatocellular Carcinoma for Dual Inhibition of mTOR.

Veiga SR, Ge X, Mercer CA, Hernández-Álvarez MI, Thomas HE, Hernandez-Losa J, Ramón Y Cajal S, Zorzano A, Thomas G, Kozma SC.

Clin Cancer Res. 2018 Aug 1;24(15):3767-3780. doi: 10.1158/1078-0432.CCR-18-0177. Epub 2018 Apr 24.

4.

Autogenous Control of 5′TOP mRNA Stability by 40S Ribosomes.

Gentilella A, Morón-Duran FD, Fuentes P, Zweig-Rocha G, Riaño-Canalias F, Pelletier J, Ruiz M, Turón G, Castaño J, Tauler A, Bueno C, Menéndez P, Kozma SC, Thomas G.

Mol Cell. 2017 Jul 6;67(1):55-70.e4. doi: 10.1016/j.molcel.2017.06.005. Epub 2017 Jun 29.

5.

A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies.

Wise-Draper TM, Moorthy G, Salkeni MA, Karim NA, Thomas HE, Mercer CA, Beg MS, O'Gara S, Olowokure O, Fathallah H, Kozma SC, Thomas G, Rixe O, Desai P, Morris JC.

Target Oncol. 2017 Jun;12(3):323-332. doi: 10.1007/s11523-017-0482-9.

6.

EPRS is a critical mTORC1-S6K1 effector that influences adiposity in mice.

Arif A, Terenzi F, Potdar AA, Jia J, Sacks J, China A, Halawani D, Vasu K, Li X, Brown JM, Chen J, Kozma SC, Thomas G, Fox PL.

Nature. 2017 Feb 16;542(7641):357-361. doi: 10.1038/nature21380. Epub 2017 Feb 8.

7.

S6K1 Phosphorylation of H2B Mediates EZH2 Trimethylation of H3: A Determinant of Early Adipogenesis.

Yi SA, Um SH, Lee J, Yoo JH, Bang SY, Park EK, Lee MG, Nam KH, Jeon YJ, Park JW, You JS, Lee SJ, Bae GU, Rhie JW, Kozma SC, Thomas G, Han JW.

Mol Cell. 2016 May 5;62(3):443-452. doi: 10.1016/j.molcel.2016.03.011. Epub 2016 Apr 14.

8.

S6K-STING interaction regulates cytosolic DNA-mediated activation of the transcription factor IRF3.

Wang F, Alain T, Szretter KJ, Stephenson K, Pol JG, Atherton MJ, Hoang HD, Fonseca BD, Zakaria C, Chen L, Rangwala Z, Hesch A, Chan ESY, Tuinman C, Suthar MS, Jiang Z, Ashkar AA, Thomas G, Kozma SC, Gale M Jr, Fitzgerald KA, Diamond MS, Mossman K, Sonenberg N, Wan Y, Lichty BD.

Nat Immunol. 2016 May;17(5):514-522. doi: 10.1038/ni.3433. Epub 2016 Apr 4.

9.

Effect of low doses of actinomycin D on neuroblastoma cell lines.

Cortes CL, Veiga SR, Almacellas E, Hernández-Losa J, Ferreres JC, Kozma SC, Ambrosio S, Thomas G, Tauler A.

Mol Cancer. 2016 Jan 4;15:1. doi: 10.1186/s12943-015-0489-8.

10.

V-ATPase: a master effector of E2F1-mediated lysosomal trafficking, mTORC1 activation and autophagy.

Meo-Evoli N, Almacellas E, Massucci FA, Gentilella A, Ambrosio S, Kozma SC, Thomas G, Tauler A.

Oncotarget. 2015 Sep 29;6(29):28057-70. doi: 10.18632/oncotarget.4812.

11.

MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells.

Cortés C, Kozma SC, Tauler A, Ambrosio S.

Cell Oncol (Dordr). 2015 Oct;38(5):341-52. doi: 10.1007/s13402-015-0233-9. Epub 2015 Aug 26.

PMID:
26306783
12.

S6K1 controls pancreatic β cell size independently of intrauterine growth restriction.

Um SH, Sticker-Jantscheff M, Chau GC, Vintersten K, Mueller M, Gangloff YG, Adams RH, Spetz JF, Elghazi L, Pfluger PT, Pende M, Bernal-Mizrachi E, Tauler A, Tschöp MH, Thomas G, Kozma SC.

J Clin Invest. 2015 Jul 1;125(7):2736-47. doi: 10.1172/JCI77030. Epub 2015 Jun 15.

13.

Role of hepatocyte S6K1 in palmitic acid-induced endoplasmic reticulum stress, lipotoxicity, insulin resistance and in oleic acid-induced protection.

Pardo V, González-Rodríguez Á, Muntané J, Kozma SC, Valverde ÁM.

Food Chem Toxicol. 2015 Jun;80:298-309. doi: 10.1016/j.fct.2015.03.029. Epub 2015 Apr 3.

PMID:
25846498
14.

A liaison between mTOR signaling, ribosome biogenesis and cancer.

Gentilella A, Kozma SC, Thomas G.

Biochim Biophys Acta. 2015 Jul;1849(7):812-20. doi: 10.1016/j.bbagrm.2015.02.005. Epub 2015 Feb 28. Review.

15.

Mechanistic target of rapamycin (Mtor) is essential for murine embryonic heart development and growth.

Zhu Y, Pires KM, Whitehead KJ, Olsen CD, Wayment B, Zhang YC, Bugger H, Ilkun O, Litwin SE, Thomas G, Kozma SC, Abel ED.

PLoS One. 2013;8(1):e54221. doi: 10.1371/journal.pone.0054221. Epub 2013 Jan 14.

16.

Rapamycin impacts positively on longevity, despite glucose intolerance induction.

Piguet AC, Martins PJ, Kozma SC.

J Hepatol. 2012 Dec;57(6):1368-9. doi: 10.1016/j.jhep.2012.06.038. Epub 2012 Jul 14. No abstract available.

17.

mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma.

Thomas HE, Mercer CA, Carnevalli LS, Park J, Andersen JB, Conner EA, Tanaka K, Matsutani T, Iwanami A, Aronow BJ, Manway L, Maira SM, Thorgeirsson SS, Mischel PS, Thomas G, Kozma SC.

Sci Transl Med. 2012 Jun 20;4(139):139ra84. doi: 10.1126/scitranslmed.3003923. Epub 2012 Apr 25.

18.

Metabolic control by S6 kinases depends on dietary lipids.

Castañeda TR, Abplanalp W, Um SH, Pfluger PT, Schrott B, Brown K, Grant E, Carnevalli L, Benoit SC, Morgan DA, Gilham D, Hui DY, Rahmouni K, Thomas G, Kozma SC, Clegg DJ, Tschöp MH.

PLoS One. 2012;7(3):e32631. doi: 10.1371/journal.pone.0032631. Epub 2012 Mar 7.

19.

A guide to analysis of mouse energy metabolism.

Tschöp MH, Speakman JR, Arch JR, Auwerx J, Brüning JC, Chan L, Eckel RH, Farese RV Jr, Galgani JE, Hambly C, Herman MA, Horvath TL, Kahn BB, Kozma SC, Maratos-Flier E, Müller TD, Münzberg H, Pfluger PT, Plum L, Reitman ML, Rahmouni K, Shulman GI, Thomas G, Kahn CR, Ravussin E.

Nat Methods. 2011 Dec 28;9(1):57-63. doi: 10.1038/nmeth.1806.

20.

Differential expression of S6K2 dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis.

Nardella C, Lunardi A, Fedele G, Clohessy JG, Alimonti A, Kozma SC, Thomas G, Loda M, Pandolfi PP.

Cancer Res. 2011 May 15;71(10):3669-75. doi: 10.1158/0008-5472.CAN-10-3962. Epub 2011 Mar 28.

21.

Selective pharmacogenetic inhibition of mammalian target of Rapamycin complex I (mTORC1) blocks long-term synaptic plasticity and memory storage.

Stoica L, Zhu PJ, Huang W, Zhou H, Kozma SC, Costa-Mattioli M.

Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3791-6. doi: 10.1073/pnas.1014715108. Epub 2011 Feb 9.

22.

mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs.

Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E, Wang X, Larsson O, Selvaraj A, Liu Y, Kozma SC, Thomas G, Sonenberg N.

Science. 2010 May 28;328(5982):1172-6. doi: 10.1126/science.1187532.

23.

S6K1 plays a critical role in early adipocyte differentiation.

Carnevalli LS, Masuda K, Frigerio F, Le Bacquer O, Um SH, Gandin V, Topisirovic I, Sonenberg N, Thomas G, Kozma SC.

Dev Cell. 2010 May 18;18(5):763-74. doi: 10.1016/j.devcel.2010.02.018.

24.

Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor.

McFarland-Mancini MM, Funk HM, Paluch AM, Zhou M, Giridhar PV, Mercer CA, Kozma SC, Drew AF.

J Immunol. 2010 Jun 15;184(12):7219-28. doi: 10.4049/jimmunol.0901929. Epub 2010 May 10.

25.

The nuclear receptor DHR3 modulates dS6 kinase-dependent growth in Drosophila.

Montagne J, Lecerf C, Parvy JP, Bennion JM, Radimerski T, Ruhf ML, Zilbermann F, Vouilloz N, Stocker H, Hafen E, Kozma SC, Thomas G.

PLoS Genet. 2010 May 6;6(5):e1000937. doi: 10.1371/journal.pgen.1000937.

26.

Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner.

Kalender A, Selvaraj A, Kim SY, Gulati P, Brûlé S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, Marette A, Kozma SC, Thomas G.

Cell Metab. 2010 May 5;11(5):390-401. doi: 10.1016/j.cmet.2010.03.014.

27.

A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis.

Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A, Trotman LC, Cheng K, Varmeh S, Kozma SC, Thomas G, Rosivatz E, Woscholski R, Cognetti F, Scher HI, Pandolfi PP.

J Clin Invest. 2010 Mar;120(3):681-93. doi: 10.1172/JCI40535. Epub 2010 Feb 8.

28.

Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production.

Alain T, Lun X, Martineau Y, Sean P, Pulendran B, Petroulakis E, Zemp FJ, Lemay CG, Roy D, Bell JC, Thomas G, Kozma SC, Forsyth PA, Costa-Mattioli M, Sonenberg N.

Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1576-81. doi: 10.1073/pnas.0912344107. Epub 2010 Jan 4.

29.

Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy.

Risson V, Mazelin L, Roceri M, Sanchez H, Moncollin V, Corneloup C, Richard-Bulteau H, Vignaud A, Baas D, Defour A, Freyssenet D, Tanti JF, Le-Marchand-Brustel Y, Ferrier B, Conjard-Duplany A, Romanino K, Bauché S, Hantaï D, Mueller M, Kozma SC, Thomas G, Rüegg MA, Ferry A, Pende M, Bigard X, Koulmann N, Schaeffer L, Gangloff YG.

J Cell Biol. 2009 Dec 14;187(6):859-74. doi: 10.1083/jcb.200903131.

30.

Ribosomal protein S6 kinase 1 signaling regulates mammalian life span.

Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, Claret M, Al-Qassab H, Carmignac D, Ramadani F, Woods A, Robinson IC, Schuster E, Batterham RL, Kozma SC, Thomas G, Carling D, Okkenhaug K, Thornton JM, Partridge L, Gems D, Withers DJ.

Science. 2009 Oct 2;326(5949):140-4. doi: 10.1126/science.1177221. Erratum in: Science. 2011 Oct 7;334(6052):39.

31.

The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment.

Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, Worley PF, Kozma SC, Powell JD.

Immunity. 2009 Jun 19;30(6):832-44. doi: 10.1016/j.immuni.2009.04.014.

32.

S6 kinase 1 knockout inhibits uninephrectomy- or diabetes-induced renal hypertrophy.

Chen JK, Chen J, Thomas G, Kozma SC, Harris RC.

Am J Physiol Renal Physiol. 2009 Sep;297(3):F585-93. doi: 10.1152/ajprenal.00186.2009. Epub 2009 May 27.

33.

S6K1 deficiency protects against apoptosis in hepatocytes.

González-Rodriguez A, Alba J, Zimmerman V, Kozma SC, Valverde AM.

Hepatology. 2009 Jul;50(1):216-29. doi: 10.1002/hep.22915.

34.

Interferon-dependent engagement of eukaryotic initiation factor 4B via S6 kinase (S6K)- and ribosomal protein S6K-mediated signals.

Kroczynska B, Kaur S, Katsoulidis E, Majchrzak-Kita B, Sassano A, Kozma SC, Fish EN, Platanias LC.

Mol Cell Biol. 2009 May;29(10):2865-75. doi: 10.1128/MCB.01537-08. Epub 2009 Mar 16.

35.

Differential requirement of mTOR in postmitotic tissues and tumorigenesis.

Nardella C, Carracedo A, Alimonti A, Hobbs RM, Clohessy JG, Chen Z, Egia A, Fornari A, Fiorentino M, Loda M, Kozma SC, Thomas G, Cordon-Cardo C, Pandolfi PP.

Sci Signal. 2009 Jan 27;2(55):ra2. doi: 10.1126/scisignal.2000189.

36.

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.

Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP.

J Clin Invest. 2008 Sep;118(9):3065-74. doi: 10.1172/JCI34739.

37.

Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.

Johansson G, Mahller YY, Collins MH, Kim MO, Nobukuni T, Perentesis J, Cripe TP, Lane HA, Kozma SC, Thomas G, Ratner N.

Mol Cancer Ther. 2008 May;7(5):1237-45. doi: 10.1158/1535-7163.MCT-07-2335.

38.

Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34.

Gulati P, Gaspers LD, Dann SG, Joaquin M, Nobukuni T, Natt F, Kozma SC, Thomas AP, Thomas G.

Cell Metab. 2008 May;7(5):456-65. doi: 10.1016/j.cmet.2008.03.002.

39.

Removal of S6K1 and S6K2 leads to divergent alterations in learning, memory, and synaptic plasticity.

Antion MD, Merhav M, Hoeffer CA, Reis G, Kozma SC, Thomas G, Schuman EM, Rosenblum K, Klann E.

Learn Mem. 2008 Jan 3;15(1):29-38. doi: 10.1101/lm.661908. Print 2008 Jan.

40.

Tumour suppressors in liver carcinogenesis.

Dufour JF, Huber O, Kozma SC, Lu X, Toftgård R.

J Hepatol. 2007 Dec;47(6):860-7. Epub 2007 Oct 1.

PMID:
17935820
41.

hvps34, an ancient player, enters a growing game: mTOR Complex1/S6K1 signaling.

Nobukuni T, Kozma SC, Thomas G.

Curr Opin Cell Biol. 2007 Apr;19(2):135-41. Epub 2007 Feb 23. Review.

PMID:
17321123
42.

S6k1 is not required for Pten-deficient neuronal hypertrophy.

Chalhoub N, Kozma SC, Baker SJ.

Brain Res. 2006 Jul 19;1100(1):32-41. Epub 2006 Jun 13.

PMID:
16777079
43.

Hypothalamic mTOR signaling regulates food intake.

Cota D, Proulx K, Smith KA, Kozma SC, Thomas G, Woods SC, Seeley RJ.

Science. 2006 May 12;312(5775):927-30.

44.

Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development.

Gangloff YG, Mueller M, Dann SG, Svoboda P, Sticker M, Spetz JF, Um SH, Brown EJ, Cereghini S, Thomas G, Kozma SC.

Mol Cell Biol. 2004 Nov;24(21):9508-16.

45.

Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity.

Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J, Thomas G.

Nature. 2004 Sep 9;431(7005):200-5. Epub 2004 Aug 11. Erratum in: Nature. 2004 Sep 23;431(7007):485.

PMID:
15306821
46.

Phytohormones participate in an S6 kinase signal transduction pathway in Arabidopsis.

Turck F, Zilbermann F, Kozma SC, Thomas G, Nagy F.

Plant Physiol. 2004 Apr;134(4):1527-35. Epub 2004 Apr 2.

47.

S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway.

Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, Mueller M, Fumagalli S, Kozma SC, Thomas G.

Mol Cell Biol. 2004 Apr;24(8):3112-24.

48.

Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2.

Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, Kozma SC, Hafen E, Bos JL, Thomas G.

Mol Cell. 2003 Jun;11(6):1457-66.

49.

Insulin regulation of insulin-like growth factor-binding protein-1 gene expression is dependent on the mammalian target of rapamycin, but independent of ribosomal S6 kinase activity.

Patel S, Lochhead PA, Rena G, Fumagalli S, Pende M, Kozma SC, Thomas G, Sutherland C.

J Biol Chem. 2002 Mar 22;277(12):9889-95. Epub 2002 Jan 9.

50.

Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K.

Kozma SC, Thomas G.

Bioessays. 2002 Jan;24(1):65-71. Review.

PMID:
11782951

Supplemental Content

Loading ...
Support Center